Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Increases By 20.2%

Palisade Bio, Inc. (NASDAQ:PALI) saw a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 25,352,984 shares, a growth of 20.2% from the January 29th total of 21,095,322 shares. Approximately 17.0% of the shares of the stock are sold short. Based on an average daily volume of 3,167,745 shares, the short-interest ratio is currently 8.0 days. Based on an average daily volume of 3,167,745 shares, the short-interest ratio is currently 8.0 days. Approximately 17.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On Palisade Bio

A number of institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company bought a new position in shares of Palisade Bio in the 4th quarter valued at about $252,000. OMERS ADMINISTRATION Corp acquired a new position in Palisade Bio during the fourth quarter worth approximately $254,000. Squarepoint Ops LLC bought a new stake in Palisade Bio in the fourth quarter valued at approximately $757,000. Atom Investors LP acquired a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $33,000. Finally, Diadema Partners LP acquired a new position in shares of Palisade Bio in the fourth quarter valued at $390,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Stifel Nicolaus started coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target on the stock. Clear Str raised Palisade Bio to a “strong-buy” rating in a report on Monday, December 29th. Piper Sandler assumed coverage on Palisade Bio in a report on Monday, December 29th. They issued an “overweight” rating and a $25.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Finally, B. Riley Financial began coverage on Palisade Bio in a report on Friday, January 9th. They set a “buy” rating and a $7.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.25.

Palisade Bio Stock Performance

NASDAQ:PALI opened at $1.69 on Wednesday. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.64. The company has a market cap of $251.81 million, a P/E ratio of -0.80 and a beta of 1.53. The stock’s 50-day simple moving average is $1.85 and its 200 day simple moving average is $1.60.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.